Trevi Therapeutics, Inc. (TRVI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.26+1.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Trevi plans two pivotal Phase 3 trials for IPF-related chronic cough. The company has FDA alignment on its development plan. It manages cash runway with recent offering proceeds. Recent stock gains of 52% show market optimism.
Trevi is loss-making with negative EPS of -0.47 expected in 2026. Recent earnings misses and litigation filings raise risks. The company has no revenue and uncertain cash flow. Clinical trial risks remain high.
The market prices in some clinical progress and capital management but lacks clear revenue or profitability expectations. Our view is cautious given ongoing losses and trial risks.
Breaks if: Cash runway falls below 12 months before next funding event
Breaks if: EPS loss worsens beyond -0.56 in 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating challenges in its clinical development while facing weak recent financial performance.
The market appears to have low expectations for TRVI, given its loss-making status and recent earnings misses. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Fundamentals may remain weak in the near term, especially given the recent decline in company momentum and the potential for further earnings misses. Management's focus on clinical trials and cash management provides some stability, but results will be critical.
The thesis hinges on the outcomes of upcoming clinical trials and the overall performance of the healthcare sector. Key triggers include guidance changes and the performance of sector bellwethers, which could influence investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Loss of FDA alignment or negative regulatory feedback by end 2026
Engage with FDA to gain regulatory alignment on clinical development plans for IPF-related chronic cough and other chronic cough indications.
Stated as a priority in 2 of last 2 quarters. Management completed an End-of-Phase 2 meeting with FDA in Q1 2026 achieving alignment on IPF-related chronic cough development plans and plans further FDA meetings for non-IPF ILD-related chronic cough. This shows delivering regulatory engagement consistent with stated priorities.
“Expect to meet with FDA regarding planned non-IPF ILD-related chronic cough trial”
“Completed End-of-Phase 2 meeting with FDA and gained overall alignment on clinical development plan”
Breaks if: Failure to initiate or significant delays in Phase 3 trials by end 2026
Advance clinical development by initiating and executing two Phase 3 trials for idiopathic pulmonary fibrosis-related chronic cough with topline results expected in 2027 and 2028.
Stated as a priority in 2 of last 2 quarters. Management initiated the Phase 3 OCEAN-1 trial in Q2 2026 and plans to start the OCEAN-2 trial in Q3 2026, with topline results expected in 2027 and 2028. This aligns with management's stated execution plans and shows delivering progress on clinical development.
“Initiated Phase 3 OCEAN-1 trial in Q2; OCEAN-2 trial expected in Q3 2026”
“Execution plans remain on track to conduct two Phase 3 trials in parallel with first trial expected to initiate in Q2 2026”
In the next 1 to 3 years, TRVI's outlook will depend on its ability to execute on clinical trials and navigate sector dynamics. Not investment advice.